Bavarian Nordic’s intention to list on NASDAQ is a strategic move to broaden its appeal to US investors and raise additional funds to accelerate clinical development of multi-tumor cancer immunotherapy CV-301 and respiratory syncytial virus vaccine MVA-BN RSV and to expand its manufacturing capacity. As a well-funded revenue generating company, it should still appeal to investors despite market headwinds. While pricing is to be determined, the likely timing of the proposed IPO represent
17 Feb 2016
Seeking a cash injection from the US
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Seeking a cash injection from the US
Bavarian Nordic A/S (BAVA:CSE) | 0 0 2.2% | Mkt Cap: 7,903m
- Published:
17 Feb 2016 -
Author:
Lala Gregorek -
Pages:
8
Bavarian Nordic’s intention to list on NASDAQ is a strategic move to broaden its appeal to US investors and raise additional funds to accelerate clinical development of multi-tumor cancer immunotherapy CV-301 and respiratory syncytial virus vaccine MVA-BN RSV and to expand its manufacturing capacity. As a well-funded revenue generating company, it should still appeal to investors despite market headwinds. While pricing is to be determined, the likely timing of the proposed IPO represent